Dow Jones
12938.67
S&P 500
1357.66
Nasdaq
2933.17
NYSE
8094.39

WKYT Breast Cancer News

Think Pink: Breast Cancer Patients Being Empowered

5:16 PM Mon, Feb 20 12

Cancer changes lives, but for one Lexington woman it put her on the road to a healthier life that helped her battle her illness. In this month's Think Pink segment, Amber Philpott introduces us to a woman who credits getting in the gym and working out for her road to recovery and beating cancer.

WKYT Breast Cancer News

Mother and Son Fight Breast Cancer Together

October is Breast Cancer Awareness Month. On October 15th thousands of runners will take to the streets in downtown Lexington in honor of those who have battled the disease. This year marks a milestone for the race and for one of the original co-founders as well. Read More

Comments

Komen Lexington Celebrates Milestones

WKYT is now a proud media partner with Komen Lexington. The organization will celebrate two major milestones this year, the first of which is this Friday night with their annual Pink Tie Gala and later this fall with the Race for the Cure in downtown Lexington. Read More

Comments

Breast Cancer News

  • Lynch Syndrome Also Linked with Breast and Pancreatic Cancer
    A study of families with Lynch Syndrome has expanded the list of cancers related to the condition carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were ...
  • Outcomes in Older Women with Breast Cancer
    Among postmenopausal women with hormone receptor positive breast cancer, the likelihood of dying from breast cancer increases with age. These results were published in the Journal of the American Medical Association.   Of the more than 200,000 cases of breast ...
  • Aromasin Provides Breast Benefit But Takes a Toll on Bone
    Among healthy postmenopausal women at increased risk of breast cancer, the aromatase inhibitor Aromasin® (exemestane) reduces the risk of breast cancer but also increases bone loss. These results were published in Lancet Oncology.    Drugs that block the effects of estrogen ...
  • Rates of Repeat Breast Cancer Surgery Vary Widely
    Among women who undergo breast conserving surgery for invasive breast cancer, the likelihood of having a second surgery varies by institution and by surgeon. These results were published in the Journal of the American Medical Association.    Breast conserving surgery (also ...
  • Avastin May Improve Breast Cancer Response Rates
    Among women with HER2 negative breast cancer that has not spread to distant sites in the body, the addition of Avastin to neoadjuvant (before surgery) chemotherapy may increase the likelihood of a complete response to treatment (a disappearance of detectable ...
  • Ovarian Suppression During Chemotherapy Fails to Improve Post-Treatment Menstrual Function
    Among young women undergoing chemotherapy for breast cancer, use of the drug triptorelin to suppress ovarian function during treatment does not appear to improve post treatment menstrual function. These results were published in the Journal of Clinical Oncology.    Fertility preservation ...
  • Oncotype DX DCIS Score Predicts Recurrence Risk for Women with DCIS
    A DCIS Score generated by the Oncotype DX breast cancer test provides information about how likely it is that breast ductal carcinoma in situ (DCIS) will recur. This may help guide decisions about whether women with DCIS need radiation therapy ...

Susan G. Komen News

  • Statement from Susan G. Komen Founder and CEO Nancy G. Brinker
    Today I accepted the resignation of Karen Handel, who has served as Senior Vice President for Policy since April 2011. I have known Karen for many years, and we both share a common commitment to our organization's lifelong mission, which must always remain our sole focus. I wish her the best in future endeavors.
  • Statement from Susan G. Komen Board of Directors and Founder and CEO Nancy G. Brinker
    We want to apologize to the American public for recent decisions that cast doubt upon our commitment to our mission of saving women’s lives.  The events of this week have been deeply unsettling for our supporters, partners and friends and all of us at Susan G. Komen.  We have been distressed at the presumption that the changes made to our funding criteria were done for political reasons or to specifically penalize Planned Parenthood.  They were not.
  • Statement from Susan G. Komen for the Cure®
      DALLAS, TX February 1, 2012 We are dismayed and extremely disappointed that actions we have taken to strengthen our granting process have been widely mischaracterized.  It is necessary to set the record straight.      Starting in 2010, Komen began ...